Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis

Table 1 Characteristics of trials included in the analysis

Ref.	NCT number	Country/regions	Study period	Number of patients		Chemotherapy regimen
				CT	CT + TT
Valle et al[1], 2021	NCT02711553	18 countries and regionsa	May, 2016 to Aug, 2017	101	106	CisGem
					102
Vogel et al[17], 2018	NCT01320254	Germany	Jul, 2011 to Dec, 2015	28	62	CisGem
Leone et al[18], 2016	NCT01389414	Italy	Jun, 2010 to Sept, 2013	44	45	GemOx
Valle et al[19], 2015	NCT00939848	UK	Apr, 2011 to Sept, 2012	60	62	CisGem
Santoro et al[21], 2015	NCT00753675	Italy	Oct, 2008 to Sept, 2012	56	58	Gemcitabine
Chen et al[20], 2015	NCT01267344	China	Dec, 2010 to May, 2012	60	62	GemOx
Moehler et al[22], 2014	NCT00661830	Germany	May, 2008 to Jul, 2011	48	49	Gemcitabine
Malka et al[23], 2014	NCT00552149	France and Germany	Oct, 2007 to Dec, 2009	74	76	GemOx
Lee et al[24], 2012	NCT01149122	South Korea	Feb, 2009 to Aug, 2010	133	135	GemOx

^a18 countries and regions include United States, Taiwan, South Korea, Turkey, Argentina, France, Russia, Spain, United Kingdom, Germany, Australia, Belgium, Hungary, Czech Republic, Sweden, Mexico, Denmark, Austria.

CT: Chemotherapy; TT: Targeted therapy; CisGem: Gemcitabine combined with Cisplatin; GemOx: Gemcitabine combined with Oxaliplatin; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival.